State Street SPDR S&P Biotech ETF
706 hedge funds and large institutions have $6.3B invested in State Street SPDR S&P Biotech ETF in 2022 Q2 according to their latest regulatory filings, with 121 funds opening new positions, 251 increasing their positions, 197 reducing their positions, and 110 closing their positions.
60% more funds holding in top 10
Funds holding in top 10: 20 → 32 (+12)
27% more repeat investments, than reductions
Existing positions increased: 251 | Existing positions reduced: 197
10% more first-time investments, than exits
New positions opened: 121 | Existing positions closed: 110
2% more call options, than puts
Call options by funds: $1.8B | Put options by funds: $1.78B
0% more funds holding
Funds holding: 703 → 706 (+3)
7.31% less ownership
Funds ownership: 97.79% → 90.48% (-7.3%)
11% less capital invested
Capital invested by funds: $7.06B → $6.3B (-$757M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$241M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$148M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$108M |
| 4 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
+$86.3M |
| 5 |
Citigroup
New York
|
+$75.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
-$189M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$161M |
| 3 |
AssetMark Inc
Concord,
California
|
-$74.7M |
| 4 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
-$52.4M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$45.8M |
XBI Hedge Fund Activity: Q2 2022 in Review
706 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q2 2022, worth a combined $6.3B — down 11% from $7.06B a quarter earlier.
Buyers outnumbered sellers: 121 funds opened new XBI positions and 110 closed out — a net gain of 11 holders — while 251 added to existing stakes and 197 trimmed.
The largest buyer was Bank of America, adding an estimated $241M. The largest seller was Matrix Capital Management Company, exiting entirely with an estimated $189M sold.
- 706 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q2 2022, up from 703 in Q1 2022.
- Funds reported $6.3B of State Street SPDR S&P Biotech ETF stock for Q2 2022, down 11% quarter-over-quarter.
- 121 funds opened new State Street SPDR S&P Biotech ETF positions in Q2 2022 and 110 closed out, a net change of +11 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q2 2022 was Bank of America, an estimated $241M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q2 2022 was Matrix Capital Management Company, an estimated $189M sold.
Based on aggregated 13F filings for Q2 2022.